Healthcare May 17, 2022 10:54 AM (GMT+8) · EqualOcean
On May 13, Lilly announced a weekly GLP-1R / GIPR dual agonist tirzepatide (trade name: mounjaro) ™） It has been approved by FDA to be listed for type 2 diabetes and is the first of its kind. In October last year, Lilly announced that it had submitted the listing application of tirzepatide using the priority evaluation voucher. Now, less than seven months later, this potential blockbuster has been approved by the FDA to enter the market. This approval is based on the phase III clinical of surpass series. In this series of clinical, tirzepatide successively beat insulin glargine, insulin degu and smeglutide head-to-head. Lilly's treatment of tirzepatide is far more than type 2 diabetes. Lilly has clinical plans for obesity, heart failure, sleep apnea and other indications.

This text is a result of machine translation.